CovidFranceV1, Main, Exploration, bibRecord, 001406

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).

Identifieur interne : 001406 ( Main/Exploration ); précédent : 001405; suivant : 001407

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).

Auteurs : Florian Slimano [France] ; Amandine Baudouin [France] ; Jérémie Zerbit [France] ; Anne Toulemonde-Deldicque [France] ; Audrey Thomas-Schoemann [France] ; Régine Chevrier [France] ; Mikaël Daouphars [France] ; Isabelle Madelaine [France] ; Bertrand Pourroy [France] ; Jean-François Tournamille [France] ; Alain Astier [France] ; Florence Ranchon [France] ; Jean-Louis Cazin [France] ; Christophe Bardin [France] ; Catherine Rioufol [France]

Source :

Cancer treatment reviews [ 1532-1967 ] ; 2020.

RBID : pubmed:32623296

Descripteurs français

KwdFr :
- Antinéoplasiques (administration et posologie), Antinéoplasiques (effets indésirables), Betacoronavirus (isolement et purification), Essais cliniques comme sujet (méthodes), Essais cliniques comme sujet (normes), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Oncologie médicale (méthodes), Oncologie médicale (normes), Pandémies (MeSH), Pharmacie (méthodes), Pharmacie (normes), Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Tumeurs (immunologie), Tumeurs (traitement médicamenteux), Tumeurs (virologie).
MESH :
- administration et posologie : Antinéoplasiques.
- effets indésirables : Antinéoplasiques.
- immunologie : Infections à coronavirus, Pneumopathie virale, Tumeurs.
- isolement et purification : Betacoronavirus.
- méthodes : Essais cliniques comme sujet, Oncologie médicale, Pharmacie.
- normes : Essais cliniques comme sujet, Oncologie médicale, Pharmacie.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale, Tumeurs.
- virologie : Infections à coronavirus, Pneumopathie virale, Tumeurs.
- Guides de bonnes pratiques cliniques comme sujet, Humains, Pandémies.

English descriptors

KwdEn :
- Antineoplastic Agents (administration & dosage), Antineoplastic Agents (adverse effects), Betacoronavirus (isolation & purification), Clinical Trials as Topic (methods), Clinical Trials as Topic (standards), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (virology), Humans (MeSH), Medical Oncology (methods), Medical Oncology (standards), Neoplasms (drug therapy), Neoplasms (immunology), Neoplasms (virology), Pandemics (MeSH), Pharmacy (methods), Pharmacy (standards), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pneumonia, Viral (virology), Practice Guidelines as Topic (MeSH).
MESH :
- chemical , administration & dosage : Antineoplastic Agents.
- chemical , adverse effects : Antineoplastic Agents.
- drug therapy : Coronavirus Infections, Neoplasms, Pneumonia, Viral.
- immunology : Coronavirus Infections, Neoplasms, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- methods : Clinical Trials as Topic, Medical Oncology, Pharmacy.
- standards : Clinical Trials as Topic, Medical Oncology, Pharmacy.
- virology : Coronavirus Infections, Neoplasms, Pneumonia, Viral.
- Humans, Pandemics, Practice Guidelines as Topic.

Abstract

The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.

DOI: 10.1016/j.ctrv.2020.102063
PubMed: 32623296
PubMed Central: PMC7308737

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000A93
to stream Main, to step Curation: 000A93

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).</title>
<author><name sortKey="Slimano, Florian" sort="Slimano, Florian" uniqKey="Slimano F" first="Florian" last="Slimano">Florian Slimano</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Champagne-Ardenne</region>
<settlement type="city">Reims</settlement>
</placeName>
<orgName type="university">Université de Reims Champagne-Ardenne</orgName>
</affiliation>
</author>
<author><name sortKey="Baudouin, Amandine" sort="Baudouin, Amandine" uniqKey="Baudouin A" first="Amandine" last="Baudouin">Amandine Baudouin</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zerbit, Jeremie" sort="Zerbit, Jeremie" uniqKey="Zerbit J" first="Jérémie" last="Zerbit">Jérémie Zerbit</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris</wicri:regionArea>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Toulemonde Deldicque, Anne" sort="Toulemonde Deldicque, Anne" uniqKey="Toulemonde Deldicque A" first="Anne" last="Toulemonde-Deldicque">Anne Toulemonde-Deldicque</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut of Pharmacy, CHU Lille, 59000 Lille</wicri:regionArea>
<placeName><region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thomas Schoemann, Audrey" sort="Thomas Schoemann, Audrey" uniqKey="Thomas Schoemann A" first="Audrey" last="Thomas-Schoemann">Audrey Thomas-Schoemann</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chevrier, Regine" sort="Chevrier, Regine" uniqKey="Chevrier R" first="Régine" last="Chevrier">Régine Chevrier</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Daouphars, Mikael" sort="Daouphars, Mikael" uniqKey="Daouphars M" first="Mikaël" last="Daouphars">Mikaël Daouphars</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Rouen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Madelaine, Isabelle" sort="Madelaine, Isabelle" uniqKey="Madelaine I" first="Isabelle" last="Madelaine">Isabelle Madelaine</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pourroy, Bertrand" sort="Pourroy, Bertrand" uniqKey="Pourroy B" first="Bertrand" last="Pourroy">Bertrand Pourroy</name>
<affiliation wicri:level="3"><nlm:affiliation>Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tournamille, Jean Francois" sort="Tournamille, Jean Francois" uniqKey="Tournamille J" first="Jean-François" last="Tournamille">Jean-François Tournamille</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours</wicri:regionArea>
<placeName><region type="region" nuts="2">Centre-Val de Loire</region>
<region type="old region" nuts="2">Région Centre</region>
<settlement type="city">Tours</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Astier, Alain" sort="Astier, Alain" uniqKey="Astier A" first="Alain" last="Astier">Alain Astier</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ranchon, Florence" sort="Ranchon, Florence" uniqKey="Ranchon F" first="Florence" last="Ranchon">Florence Ranchon</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cazin, Jean Louis" sort="Cazin, Jean Louis" uniqKey="Cazin J" first="Jean-Louis" last="Cazin">Jean-Louis Cazin</name>
<affiliation wicri:level="3"><nlm:affiliation>Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille</wicri:regionArea>
<placeName><region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bardin, Christophe" sort="Bardin, Christophe" uniqKey="Bardin C" first="Christophe" last="Bardin">Christophe Bardin</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris</wicri:regionArea>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rioufol, Catherine" sort="Rioufol, Catherine" uniqKey="Rioufol C" first="Catherine" last="Rioufol">Catherine Rioufol</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32623296</idno>
<idno type="pmid">32623296</idno>
<idno type="doi">10.1016/j.ctrv.2020.102063</idno>
<idno type="pmc">PMC7308737</idno>
<idno type="wicri:Area/Main/Corpus">000A93</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A93</idno>
<idno type="wicri:Area/Main/Curation">000A93</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A93</idno>
<idno type="wicri:Area/Main/Exploration">000A93</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).</title>
<author><name sortKey="Slimano, Florian" sort="Slimano, Florian" uniqKey="Slimano F" first="Florian" last="Slimano">Florian Slimano</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Champagne-Ardenne</region>
<settlement type="city">Reims</settlement>
</placeName>
<orgName type="university">Université de Reims Champagne-Ardenne</orgName>
</affiliation>
</author>
<author><name sortKey="Baudouin, Amandine" sort="Baudouin, Amandine" uniqKey="Baudouin A" first="Amandine" last="Baudouin">Amandine Baudouin</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zerbit, Jeremie" sort="Zerbit, Jeremie" uniqKey="Zerbit J" first="Jérémie" last="Zerbit">Jérémie Zerbit</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris</wicri:regionArea>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Toulemonde Deldicque, Anne" sort="Toulemonde Deldicque, Anne" uniqKey="Toulemonde Deldicque A" first="Anne" last="Toulemonde-Deldicque">Anne Toulemonde-Deldicque</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut of Pharmacy, CHU Lille, 59000 Lille</wicri:regionArea>
<placeName><region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thomas Schoemann, Audrey" sort="Thomas Schoemann, Audrey" uniqKey="Thomas Schoemann A" first="Audrey" last="Thomas-Schoemann">Audrey Thomas-Schoemann</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chevrier, Regine" sort="Chevrier, Regine" uniqKey="Chevrier R" first="Régine" last="Chevrier">Régine Chevrier</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Daouphars, Mikael" sort="Daouphars, Mikael" uniqKey="Daouphars M" first="Mikaël" last="Daouphars">Mikaël Daouphars</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Rouen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Madelaine, Isabelle" sort="Madelaine, Isabelle" uniqKey="Madelaine I" first="Isabelle" last="Madelaine">Isabelle Madelaine</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pourroy, Bertrand" sort="Pourroy, Bertrand" uniqKey="Pourroy B" first="Bertrand" last="Pourroy">Bertrand Pourroy</name>
<affiliation wicri:level="3"><nlm:affiliation>Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tournamille, Jean Francois" sort="Tournamille, Jean Francois" uniqKey="Tournamille J" first="Jean-François" last="Tournamille">Jean-François Tournamille</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours</wicri:regionArea>
<placeName><region type="region" nuts="2">Centre-Val de Loire</region>
<region type="old region" nuts="2">Région Centre</region>
<settlement type="city">Tours</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Astier, Alain" sort="Astier, Alain" uniqKey="Astier A" first="Alain" last="Astier">Alain Astier</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ranchon, Florence" sort="Ranchon, Florence" uniqKey="Ranchon F" first="Florence" last="Ranchon">Florence Ranchon</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cazin, Jean Louis" sort="Cazin, Jean Louis" uniqKey="Cazin J" first="Jean-Louis" last="Cazin">Jean-Louis Cazin</name>
<affiliation wicri:level="3"><nlm:affiliation>Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille</wicri:regionArea>
<placeName><region type="region" nuts="2">Hauts-de-France</region>
<region type="old region" nuts="2">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bardin, Christophe" sort="Bardin, Christophe" uniqKey="Bardin C" first="Christophe" last="Bardin">Christophe Bardin</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris</wicri:regionArea>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
<wicri:noRegion>75 014 Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rioufol, Catherine" sort="Rioufol, Catherine" uniqKey="Rioufol C" first="Catherine" last="Rioufol">Catherine Rioufol</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Cancer treatment reviews</title>
<idno type="eISSN">1532-1967</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (administration & dosage)</term>
<term>Antineoplastic Agents (adverse effects)</term>
<term>Betacoronavirus (isolation & purification)</term>
<term>Clinical Trials as Topic (methods)</term>
<term>Clinical Trials as Topic (standards)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Humans (MeSH)</term>
<term>Medical Oncology (methods)</term>
<term>Medical Oncology (standards)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (immunology)</term>
<term>Neoplasms (virology)</term>
<term>Pandemics (MeSH)</term>
<term>Pharmacy (methods)</term>
<term>Pharmacy (standards)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Practice Guidelines as Topic (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (administration et posologie)</term>
<term>Antinéoplasiques (effets indésirables)</term>
<term>Betacoronavirus (isolement et purification)</term>
<term>Essais cliniques comme sujet (méthodes)</term>
<term>Essais cliniques comme sujet (normes)</term>
<term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Oncologie médicale (méthodes)</term>
<term>Oncologie médicale (normes)</term>
<term>Pandémies (MeSH)</term>
<term>Pharmacie (méthodes)</term>
<term>Pharmacie (normes)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Tumeurs (immunologie)</term>
<term>Tumeurs (traitement médicamenteux)</term>
<term>Tumeurs (virologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Neoplasms</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Neoplasms</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Medical Oncology</term>
<term>Pharmacy</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Essais cliniques comme sujet</term>
<term>Oncologie médicale</term>
<term>Pharmacie</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Essais cliniques comme sujet</term>
<term>Oncologie médicale</term>
<term>Pharmacie</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Medical Oncology</term>
<term>Pharmacy</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Neoplasms</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Pandemics</term>
<term>Practice Guidelines as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Guides de bonnes pratiques cliniques comme sujet</term>
<term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32623296</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1967</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>88</Volume>
<PubDate><Year>2020</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Cancer treatment reviews</Title>
<ISOAbbreviation>Cancer Treat. Rev.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).</ArticleTitle>
<Pagination><MedlinePgn>102063</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0305-7372(20)30101-8</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctrv.2020.102063</ELocationID>
<Abstract><AbstractText>The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Slimano</LastName>
<ForeName>Florian</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baudouin</LastName>
<ForeName>Amandine</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zerbit</LastName>
<ForeName>Jérémie</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Toulemonde-Deldicque</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thomas-Schoemann</LastName>
<ForeName>Audrey</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chevrier</LastName>
<ForeName>Régine</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Daouphars</LastName>
<ForeName>Mikaël</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Madelaine</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pourroy</LastName>
<ForeName>Bertrand</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tournamille</LastName>
<ForeName>Jean-François</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Astier</LastName>
<ForeName>Alain</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ranchon</LastName>
<ForeName>Florence</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cazin</LastName>
<ForeName>Jean-Louis</ForeName>
<Initials>JL</Initials>
<AffiliationInfo><Affiliation>Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bardin</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rioufol</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Cancer Treat Rev</MedlineTA>
<NlmUniqueID>7502030</NlmUniqueID>
<ISSNLinking>0305-7372</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010604" MajorTopicYN="N">Pharmacy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Clinical trials</Keyword>
<Keyword MajorTopicYN="N">Drug safety</Keyword>
<Keyword MajorTopicYN="N">Drug-drug interactions</Keyword>
<Keyword MajorTopicYN="N">Drug-related problems</Keyword>
<Keyword MajorTopicYN="N">Herb-Drug interactions</Keyword>
<Keyword MajorTopicYN="N">Immune depression</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32623296</ArticleId>
<ArticleId IdType="pii">S0305-7372(20)30101-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.ctrv.2020.102063</ArticleId>
<ArticleId IdType="pmc">PMC7308737</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Auvergne (région administrative)</li>
<li>Auvergne-Rhône-Alpes</li>
<li>Centre-Val de Loire</li>
<li>Champagne-Ardenne</li>
<li>Grand Est</li>
<li>Haute-Normandie</li>
<li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Rhône-Alpes</li>
<li>Région Centre</li>
<li>Région Normandie</li>
<li>Île-de-France</li>
</region>
<settlement><li>Clermont-Ferrand</li>
<li>Créteil</li>
<li>Lille</li>
<li>Lyon</li>
<li>Marseille</li>
<li>Paris</li>
<li>Reims</li>
<li>Rouen</li>
<li>Tours</li>
</settlement>
<orgName><li>Université de Reims Champagne-Ardenne</li>
</orgName>
</list>
<tree><country name="France"><region name="Grand Est"><name sortKey="Slimano, Florian" sort="Slimano, Florian" uniqKey="Slimano F" first="Florian" last="Slimano">Florian Slimano</name>
</region>
<name sortKey="Astier, Alain" sort="Astier, Alain" uniqKey="Astier A" first="Alain" last="Astier">Alain Astier</name>
<name sortKey="Bardin, Christophe" sort="Bardin, Christophe" uniqKey="Bardin C" first="Christophe" last="Bardin">Christophe Bardin</name>
<name sortKey="Baudouin, Amandine" sort="Baudouin, Amandine" uniqKey="Baudouin A" first="Amandine" last="Baudouin">Amandine Baudouin</name>
<name sortKey="Cazin, Jean Louis" sort="Cazin, Jean Louis" uniqKey="Cazin J" first="Jean-Louis" last="Cazin">Jean-Louis Cazin</name>
<name sortKey="Chevrier, Regine" sort="Chevrier, Regine" uniqKey="Chevrier R" first="Régine" last="Chevrier">Régine Chevrier</name>
<name sortKey="Daouphars, Mikael" sort="Daouphars, Mikael" uniqKey="Daouphars M" first="Mikaël" last="Daouphars">Mikaël Daouphars</name>
<name sortKey="Madelaine, Isabelle" sort="Madelaine, Isabelle" uniqKey="Madelaine I" first="Isabelle" last="Madelaine">Isabelle Madelaine</name>
<name sortKey="Pourroy, Bertrand" sort="Pourroy, Bertrand" uniqKey="Pourroy B" first="Bertrand" last="Pourroy">Bertrand Pourroy</name>
<name sortKey="Ranchon, Florence" sort="Ranchon, Florence" uniqKey="Ranchon F" first="Florence" last="Ranchon">Florence Ranchon</name>
<name sortKey="Rioufol, Catherine" sort="Rioufol, Catherine" uniqKey="Rioufol C" first="Catherine" last="Rioufol">Catherine Rioufol</name>
<name sortKey="Thomas Schoemann, Audrey" sort="Thomas Schoemann, Audrey" uniqKey="Thomas Schoemann A" first="Audrey" last="Thomas-Schoemann">Audrey Thomas-Schoemann</name>
<name sortKey="Toulemonde Deldicque, Anne" sort="Toulemonde Deldicque, Anne" uniqKey="Toulemonde Deldicque A" first="Anne" last="Toulemonde-Deldicque">Anne Toulemonde-Deldicque</name>
<name sortKey="Tournamille, Jean Francois" sort="Tournamille, Jean Francois" uniqKey="Tournamille J" first="Jean-François" last="Tournamille">Jean-François Tournamille</name>
<name sortKey="Zerbit, Jeremie" sort="Zerbit, Jeremie" uniqKey="Zerbit J" first="Jérémie" last="Zerbit">Jérémie Zerbit</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001406 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001406 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32623296
   |texte=   Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32623296" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki